Your browser doesn't support javascript.
loading
WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function.
Yoon, Hyun Ju; Kim, Gi-Cheon; Oh, Sejin; Kim, Hakhyun; Kim, Yong Keon; Lee, Yunji; Kim, Min Seo; Kwon, Gino; Ok, Yeon-Su; Kwon, Ho-Keun; Kim, Hyun Seok.
Afiliación
  • Yoon HJ; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Kim GC; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • Oh S; Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul, Korea.
  • Kim H; Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea.
  • Kim YK; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Lee Y; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • Kim MS; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • Kwon G; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Ok YS; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • Kwon HK; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
  • Kim HS; Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
Exp Mol Med ; 54(11): 1913-1926, 2022 11.
Article en En | MEDLINE | ID: mdl-36357569
Immune checkpoint therapies, such as programmed cell death ligand 1 (PD-L1) blockade, have shown remarkable clinical benefit in many cancers by restoring the function of exhausted T cells. Hence, the identification of novel PD-L1 regulators and the development of their inhibition strategies have significant therapeutic advantages. Here, we conducted pooled shRNA screening to identify regulators of membrane PD-L1 levels in lung cancer cells targeting druggable genes and cancer drivers. We identified WNK lysine deficient protein kinase 3 (WNK3) as a novel positive regulator of PD-L1 expression. The kinase-dead WNK3 mutant failed to elevate PD-L1 levels, indicating the involvement of its kinase domain in this function. WNK3 perturbation increased cancer cell death in cancer cell-immune cell coculture conditions and boosted the secretion of cytokines and cytolytic enzymes, promoting antitumor activities in CD4+ and CD8+ T cells. WNK463, a pan-WNK inhibitor, enhanced CD8+ T-cell-mediated antitumor activity and suppressed tumor growth as a monotherapy as well as in combination with a low-dose anti-PD-1 antibody in the MC38 syngeneic mouse model. Furthermore, we demonstrated that the c-JUN N-terminal kinase (JNK)/c-JUN pathway underlies WNK3-mediated transcriptional regulation of PD-L1. Our findings highlight that WNK3 inhibition might serve as a potential therapeutic strategy for cancer immunotherapy through its concurrent impact on cancer cells and immune cells.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Serina-Treonina Quinasas / Linfocitos T CD8-positivos / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Exp Mol Med Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Serina-Treonina Quinasas / Linfocitos T CD8-positivos / Antígeno B7-H1 / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Exp Mol Med Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos